A Study to Evaluate the Effect of Far Infrared Radiation for Cancer Treatment

August 14, 2009 updated by: GAAD Medical Research Institute Inc.

Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation for Cancer Treatment

Cancer is the number one killer in Canada and in most countries of the world. The investigators' initial assessment indicates that far infrared radiation has the potential to cure cancer.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The investigators have identified a combination of methods for possible cancer treatment as follows:

  1. Energy specific far infrared radiation (5 μm to 20 μm ). No x-rays, gamma rays etc. are used.
  2. Oxygenation of the body cells
  3. pH balance
  4. Lifestyle changes, or
  5. A combination of chemotherapy and (1), (2), (3) and (4) above.

Study Type

Interventional

Enrollment (Actual)

3

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Toronto, Ontario, Canada, M4V 1L5
        • The Centre for Incurable Diseases

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • All cancer patients

Exclusion Criteria:

  • non-cancer patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: 1
Infrared Radiation
Radiation: Far Infrared Radiation
Far Infrared Radiation (5μm to 20μm wavelength)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The effect of far infrared radiation on cancerous tumours
Time Frame: 1 year
1 year

Secondary Outcome Measures

Outcome Measure
Time Frame
The effect on far infrared treatment on different kinds of cancer.
Time Frame: 1 year
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

GAAD Medical Research Institute Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2008

Primary Completion (Actual)

August 1, 2009

Study Completion (Anticipated)

October 1, 2009

Study Registration Dates

First Submitted

December 12, 2007

First Submitted That Met QC Criteria

December 12, 2007

First Posted (Estimate)

December 14, 2007

Study Record Updates

Last Update Posted (Estimate)

August 17, 2009

Last Update Submitted That Met QC Criteria

August 14, 2009

Last Verified

August 1, 2009

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • GAAD-CAN-CTP1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neoplasms

Clinical Trials on Far Infrared Radiation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe